About US
Contact us
-
Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and PfizerAfter issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody linvoseltamab, the company has crossed the regulatory finish line with its new dru2025/4/29
-
As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defenseWith an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. That’s how Biljana Naumovic, president of J&J’s U.S. solid tumor business, de2025/4/29
-
Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trialAkeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit Therap2025/4/24
-
Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtypeAkeso is on a winning streak. Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso haswon the FDA’s go-aheadfor its PD-1 inhibitor penpulimab co-developed with2025/4/24
-
US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutideMakers of knockoff in-demand weight loss drugs are fast running out of options to manufacture them legitimately as a federal court this week dismissed an attempt by compounding pharmacies to continue2025/4/22
-
Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyoutMerck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmakerconfirmed(PDF) it is in late-stage talks about buying the rare cancer biopharma for around2025/4/22
-
Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall throughHalozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New J2025/4/17
-
Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPDAs Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, fulfilling that goal will hinge on its uptake in chronic obstructive pulmonary2025/4/17
-
Roche moves to mitigate US tariff impact amid discussions with global governmentsRoche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning the President Trump administration for an exemption. Roche is trying to r2025/4/15
-
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctiveSchizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive treatment2025/4/15